Please sign in to follow a disease.
Pemphigus
MONDO:0006594Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals).This conditioncan occur at any age, but often strikes people in middle or older age. Studies have shown that some populations may be at greater risk for certain types of pemphigus. For instance, people of Jewish descent and those from India, Southeast Europe, and the Middle East are at greater risk for pemphigus vulargis, while pemphigus foliaceus is more common in North America, Turkey, and South America. Pemphigus is a chronic disease which is best controlled by early diagnosis and treatment.Treatment includes steroids to reduce inflammation,drugs that suppress the immune system responseand antibiotics to treat associated infections. There are four main types of pemphigus: Pemphigus vulgaris Pemphigus foliaceus IgA pemphigus Paraneoplastic pemphigus
63 clinical trials for this condition and its sub-types, 20 tagged with Pemphigus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pemphigus
-
Pemphigus vulgaris 13 trials
1 sub-type
- Pemphigus vegetans 0 trials
-
Pemphigus foliaceus 3 trials · 6 incl. sub-types
1 sub-type
- Pemphigus and fogo selvagem 3 trials
-
Hailey-Hailey disease 3 trials
-
Herpetiform pemphigus 0 trials
-
Pemphigoid gestationis 0 trials
-
Pemphigus erythematosus 0 trials
-
Could stem cells plus supercharged immune cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune diseases
Disease control Not yet recruitingThis study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Fetal stem cells aim to tame immune chaos
Disease control Not yet recruitingThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted biologic outperform standard care for a rare blistering disease?
Disease control Not yet recruitingThis trial compares two treatment approaches for moderate to severe pemphigus vulgaris, a rare autoimmune disease causing painful blisters on skin and mucous membranes. One group receives rituximab (a biologic that targets immune B-cells) plus corticosteroids, while the other get…
Early phase 1 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T injection aims to tame autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…
Early phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control Not yet recruitingThis study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …
Phase 1/2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
A finger prick instead of a needle: could At-Home blood tests match hospital accuracy?
Diagnosis Not yet recruitingThis study tests whether blood samples collected at home using small capillary devices, like finger pricks, give the same results as traditional blood draws from a vein. Researchers will compare both methods in about 1,000 people with chronic conditions such as kidney disease, au…
Sponsor: University of Edinburgh • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
Can a 20-Minute video make teens Disaster-Ready?
Prevention Not yet recruitingThis trial tests whether a short, purpose-built educational video can strengthen high-school students' belief in disaster preparedness and their perception of disaster risk. About 144 students from twelve classes at one school in West Kalimantan, Indonesia, will be randomly assig…
Sponsor: Tanjungpura University • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 20, 2026 00:00 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can immune fingerprints unlock new treatments for skin disease?
Knowledge-focused Not yet recruitingThis observational study aims to map the immune and molecular profiles of people with inflammatory skin conditions, including genetic forms like epidermolysis bullosa. By comparing these profiles to those of healthy individuals, researchers hope to identify unique signatures that…
Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Statins vs. smoke: can a pill protect your heart and brain?
Knowledge-focused Not yet recruitingThis study tests whether taking statins (a common cholesterol drug) can protect the heart and brain from the harmful effects of breathing bushfire smoke. Healthy adults aged 18-64 will be exposed to simulated smoke in a controlled setting, with some taking statins short-term (2 d…
Phase 4 • Sponsor: Menzies Institute for Medical Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC